Tilray Archives - Green Market Report

Debra BorchardtDebra BorchardtAugust 21, 2019
globe.jpg

3min800

Tilray, Inc. (NASDAQ: TLRY) said that it has entered into an agreement with Cannamedical Pharma GmbH through its wholly-owned subsidiary Tilray Portugal Unipessoal Lda. to export a wholesale shipment of $3.3 (€3) million worth of medical cannabis from Portugal to Germany. The shipment, which is expected to be completed in fall 2019, will be Tilray’s first from its state-of-the-art EU campus in Portugal to supply patients in Germany.

“This is a significant milestone for Tilray as we ramp up our capacity to serve international markets and generate revenue from our EU campus through the end of 2019,” says Tilray CEO Brendan Kennedy. “We believe our 2.5 million square feet of cultivation and state-of-the-art processing space in Europe is an important differentiator, which will enable us to reduce costs and improve margins while hedging against regulatory risk.”

Roughly 5.5 % of Tilray’s revenues are generated in Germany, but Cowen & Co. analyst Vivien Azer believes international markets could represent approximately $2.8 billion in business as the company expands into other countries. She has forecast that by 2021, the international business could contribute 30% of the company’s total sales.

Germany based Cannamedical is fully licensed and GDP-certified to import and distribute high-quality medical cannabis products. The privately-owned company is a leading independent supplier of medical cannabis products to 2,500 pharmacies and clinical facilities across Germany.

“We at Cannamedical Pharma are committed to helping doctors, medical specialists and pharmacists improve their patients’ quality of life,” says Cannamedical CEO David Henn. “Tilray’s product has passed our strict quality control standards, and we’re excited to have found a partner able to deliver medical cannabis products for use in Cannamedical’s own brands. We look forward to increasing access for patients in need across the country.”

According to Azer, the international growth for Tilray is expected to be driven by Germany, then followed by Australia, New Zealand, and other countries. She thinks the three countries mentioned will be a $1.1 billion medical cannabis market by 2021.

“We are pleased to enter into an agreement with a partner who shares Tilray’s commitment to product quality and safety and patient access,” says Sascha Mielcarek, Tilray’s Managing Director, Europe. “This initial shipment will be the first of many from our EU Campus in Portugal to Germany as well as other European and international markets.”


Debra BorchardtDebra BorchardtAugust 13, 2019
brody-tilray-pack1-1280x675.jpg

3min2070

Tilray, Inc. (Nasdaq: TLRY) reported financial results for the second quarter ending June 30, 2019 revenue increased 371.1% to $45.9 (C$60.9) million, compared to the second quarter of last year, driven by the Manitoba Harvest acquisition, the legalization of the Canadian adult-use market, and growth in international medical markets, particularly in Europe. Excluding excise tax, revenue was $42.0 (C$55.8) million.

The company reported a net loss of $35.1 million or $0.36 per share compared to a loss of $12.8 million or $0.17 per share for the same time period in 2018. The adjusted net loss for the quarter was $31.2 million or $0.32 per share for the second quarter of 2019. Tilray said that the adjustments to the net loss were non-recurring acquisition-related charges and a non-recurring non-cash charge related to purchase accounting for the fair value of inventory.

The company’s stock was falling in after-hours trading by over 5% to $43.35.

The adjusted EBITDA was a loss of $17.9 million compared to a loss of $4.7 million last year. The increased net loss and adjusted EBITDA declines were primarily due to the increase in operating expenses related to growth initiatives, interest expense from our convertible notes, the addition of Manitoba Harvest and Natura businesses, and the expansion of international operations.

“We are pleased with our second quarter results and strong business momentum,” said Brendan Kennedy, Tilray President and Chief Executive Officer. “Our team has executed against our plan, with adult-use revenue nearly doubling in the second quarter compared to the first quarter and gross margin increasing sequentially for the second quarter in a row. As we continue to grow, we remain focused on our long-term strategic objectives and deploying capital to maximize stockholder value.”

Kilograms Sold Tripled

The company said its total kilograms sold more than tripled to 5,588 kilograms from 1,514 kilograms in the prior-year period. The average net selling price per gram dropped to $4.61 (C$6.12) compared to $6.38 (C$8.36) in the prior-year period. The average net selling price excluding excise taxes was $3.92 (C$5.20) per gram for the second quarter of 2019. The decrease was due to a reduced mix of higher-priced extract products and a greater mix of adult-use revenue, which are at lower prices per gram compared to other channels.

 


William SumnerWilliam SumnerJuly 23, 2019
stock-1863880_640.jpg

3min3360

Amplify Investments is getting into the cannabis industry. Today, Amplify ETF’s announced the launch of Amplify Seymour Cannabis ETF (NYSE Arca: CNBS), an actively managed ETF covering the cannabis industry. Tim Seymour, CIO of Seymour Asset Management and CNBC Fast Money co-host, will act as the fund’s portfolio manager.

As one of the world’s most premier financial journalists, Seymour recently served as the headline speaker for the Green Market Summit in Chicago, Illinois. You can watch his fireside chat with Peter Miller, CEO of Slang Worldwide Inc. (SLGWF), about the explosive growth of the cannabis industry here.

“The global legal cannabis industry is still very much in its infancy and presents an attractive growth opportunity for investors looking to capitalize on this emerging frontier,” Seymour said. “Amplify has a track record of offering investors access to disruptive areas of the market via the ETF structure, and the cannabis industry certainly fits this mold.”

As portfolio manager, Seymour will base his decisions off of publicly available data, regulatory filings, third party research, and his evaluations of companies’ financial fundamentals.

The CNBS portfolio will include cannabis companies that are federally legal in the countries in which they operate. Specifically, the portfolio will cover companies that fall into one of three categories: cannabis/hemp plant, support cultivation and retail, and ancillary companies that provide goods and services to the cannabis industry.

Another qualification is that at least 80% of the companies in the ETF must receive 50% or more of their revenue from the hemp or cannabis industry. The fund portfolio currently covers 25 of the cannabis industry’s leading companies; such as Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), Hexo Corp. (NYSE: HEXO), Tilray (NASDAQ: TLRY), and WeedMD (OTCMKTS: WDDMF)

“Cannabis and hemp are seeing a new wave of potential use cases across multiple industries, and investors are eager to gain access to this emerging sector,” said Christian Magoon, founder and CEO of Amplify ETFs. “Tim is a recognized voice and active investor in the cannabis space, and we’re excited to harness his investment expertise and specialized insights to navigate and capture the expanding opportunity in the rapidly evolving industry.”


William SumnerWilliam SumnerJune 13, 2019
daily_hit004-1280x533.png

6min3470

It’s time for your Daily Hit of cannabis financial news for June 13, 2019.

On the Site

Cannabis’ Black Market Continues to Thrive Amidst Continued Legalization

Despite legalization continuing to spread, and efforts advocating towards federal legalization of cannabis, the black market in the U.S. for cannabis continues to thrive across the nation.Simply put, despite access and legal product being available, people are still as or more likely to purchase their cannabis from black market sources, with this trend not showing any signs of stopping.

HEXO Corp.

HEXO Corp (TSX:HEXO) ( NYSE-A:HEXO)  reported its financial results for the third quarter of the 2019 fiscal year with $15.9 million in gross revenues and a net loss of $7.7 million. The company claims it is on track to reach $400 million in net revenue in 2020 and says it will double net revenue in the fourth fiscal quarter.

Executive Spotlight: Amanda Ostrowitz, Founder & CEO of RegsTechnology

Amanda Ostrowitz is a regulatory attorney and entrepreneur who’s identified a need for a user- friendly, scalable platform to research regulations and laws in the cannabis industry. Amanda founded RegsTechnology and its current product, CannaRegs, as a tool to aid attorneys, business people, and governments with localized tracking of regulatory issues.

MJMicro Conference

Although adult-use cannabis is legal in nine U.S. states, problems persist with companies trying to gain access to capital and essential financial services. Consequently, the industry has devised a series of methods and institutions to circumvent these difficulties; from credit unions to keeping their funds in a giant safe. Another unique way that the cannabis industry has adapted to the issue has been connecting companies with private capital investment through investor forums. A perfect example of this is the MJMicro Conference planned for June 25, 2019, in New York City.

In Other News

Tilray

Tilray, Inc. (NASDAQ: TLRY) today announced the appointment of Kristina Adamski as Executive Vice President, Corporate Affairs. Adamski will help coordinate the company’s corporate affairs team and help oversee the company’s public relations, corporate social responsibility and government affairs functions. Adamski previously served as Nissan North America’s Vice President of Corporate Communications for more than three years. “We’re thrilled to welcome Kristina to our growing senior leadership team. We’re confident that her vast experience in corporate affairs and global communications will support Tilray’s long term global growth strategy as we expand around the world,” says Brendan Kennedy, CEO, Tilray.

Treehouse REIT

Treehouse Real Estate Investment Trust, Inc. announced that it has closed on nearly a $16 million debt commitment with a large, federally insured and regulated commercial bank. As the company continues to acquire cannabis-use properties, the note commitment will carry a 5.6% interest rate and provides for a revolving facility for future notes. “Treehouse is excited to announce that we have successfully procured federally insured commercial bank financing,” said Brian Kabot, Stable Road Capital Chief Investment Officer and Treehouse Board Member. “The capital relationship allows us to continue executing cannabis-related real estate acquisitions in a scaled, non-dilutive manner that is most accretive to our investors. We are witnessing federally regulated lenders enter the cannabis space and we are thrilled to be at the forefront of those efforts.”

Canndescent

The luxury cannabis brand Canndescent announced that it has signed a definitive agreement to acquire buildings and operating licenses in Nevada, Michigan and Massachusetts for $28.5 million. The acquired building will be retrofitted to support the company’s proprietary cultivation and extraction methods. “Our expansion is a huge win for cannabis consumers as the best of California cannabis will finally be available in other markets,” said Canndescent CEO Adrian Sedlin. “We’re sort of the ‘anti-MSO’ or as I like to call it, we’re an MSBO, Multi-State Brand Operator, having nailed brand and execution first and now rolling up assets with intentionality and understanding.”


Debra BorchardtDebra BorchardtJune 10, 2019
ClosingBell-tilray-Nasdaq-1280x854.jpg

4min2170

When Tilray, Inc. (NASDAQ: TLRY) shares first began trading the stock blew up in price sparking a rally in all cannabis stocks, but also causing concern over a cannabis stock bubble. One of the main reasons why the stock skyrocketed in those early days was a lack of tradable shares. Privateer Holdings Inc. owned a majority of the shares and they weren’t available to the market until now.

Tilray has signed a non-binding Letter of Intent (LOI) with Privateer that will extend the lock-up on and provide for the orderly release of the 75 million of its shares held by Privateer to Privateer’s equity holders. According to the company, these shares currently represent 77% of Tilray’s total shares outstanding.

“We appreciate the long-term confidence that Privateer has in the Tilray business and we look forward to having their investors as part of our stockholder base,” said Mark Castaneda, Chief Financial Officer of Tilray. “We believe this transaction will give Tilray greater control and operating flexibility while allowing us to effectively manage our public float.”

The statement said that the parties will effect a downstream merger of Privateer with and into a wholly-owned subsidiary of Tilray, with the Tilray subsidiary surviving the merger, and the issuance by Tilray to Privateer stockholders of newly issued shares of Tilray common stock in an equal amount of the shares held. The original Tilray shares that the Privateer owners held will be canceled at the merger’s completion.

Tilray was originally incubated and financed by Privateer as one of its wholly-owned operating subsidiaries before closing a Series A round of capital in February 2018 and then becoming the first cannabis producer to complete an Initial Public Offering on NASDAQ (NDAQ) in July 2018. Some Wall Street analysts were uncomfortable with the lack of liquidity of Tilray shares due to the Privateer ownership and this move would remove those concerns.

Privateer said that earlier this year it distributed its ownership of its three other operating subsidiaries unrelated to Tilray directly to Privateer stockholders, leaving no material assets in Privateer other than the 75 million shares it currently holds in Tilray.

Terms

The company said that “Pursuant to the terms of the proposed transaction, the shares of Tilray stock distributed in the merger would be subject to a lock-up allowing for the sale of such shares only under certain circumstances over a two-year period. During the first year following the closing of the merger, shares will be released only pursuant to marketed offerings and/or block trades to institutional investors or via stock sales to strategic investors, all of which would be arranged at the sole discretion of Tilray. The remaining shares will be subject to a staggered release over the course of the second year following closing. In addition, Privateer has agreed in the LOI to a lock-up on its Tilray shares during the negotiating period for the definitive merger agreement.”

Michael Blue, Managing Partner of Privateer, said: “We believe this structure will maximize overall returns for our visionary investors in a tax-efficient manner while giving Tilray the operating flexibility it needs to continue to be a leader in the rapidly emerging global cannabis industry.”


William SumnerWilliam SumnerMay 23, 2019
daily_hit004-1280x533.png

5min3100

It’s time for your Daily Hit of cannabis financial news for May 23, 2019.

On the Site

Why Canopy Growth’s Deals May Not Translate Into Gains for CGC Stock

Canopy Growth (NYSE: CGC) moved higher after announcing a deal with its investment arm, Canopy Rivers (OTCMKTS: CNPOF). This offers some relief to CGC stock, which had returned to levels not seen since before they announced their buyout intentions on Acreage Holdings (OTCMKTS: ACRGF). Unfortunately, Canopy Growth stock seems to need more.

In Other News

TerrAscend

TerrAscend Corp. (CSE: TER) (OTCQX: TRSSF) reported its financial results for the first quarter of 2019. Revenue was $14.6 milion, up from $5 million in the previous quarter. Adjusted EBITDA was $7.2 million, up from a loss of $7.1 million in the last quarter. “Our sales in Canada continue to be strong, driven by demand from provincial distributors and consumers,” said Michael Nashat, TerrAscend’s CEO. “We are building industry-leading cultivation and processing capabilities. Our Mississauga facility was recently GMP certified by the German authorities – the only such certification granted in the last year – and exports to the EU will commence this quarter.”

MedMen Enterprises

MedMen Enterprises Inc. (CSE: MMEN) (OTCQX: MMNFF) (FSE: A2JM6N) announced that it has been advanced an additional $80 million in accordance with a $250 million secured convertible credit facility with Gotham Green Partners. The company has issued additional convertible senior secured notes to the lenders with a conversion per subordinate voting share of the company equal to $3.29 per share.

Tilray

Tilray, Inc. (NASDAQ: TLRY) announced that its wholly owned subsidiary Tilray Portugal Unipessoal Lda. (Tilray Portugal) has received manufacturing licensed and a Good Manufacturing Practices certification for its Biocant Park manufacturing facility in Cantanhede, Portugal. “This licensing and certification marks a critical milestone for our growth in Portugal and Europe,” said Sascha Mielcarek, Tilray Managing Director, Europe. “The next phase of GMP certification will allow us to utilize the full capacity of our multi-faceted facility and continue to serve more patients in-need.”

Green Thumb Industries

Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) announced that it has closed a $105 million senior secured non-brokered private placement financing through the issuance of senior secured notes. The notes will mature on May 22, 2022 and will bear a annual interest rate of 12%, with an option for GTI to extend the date by an additional 12 months. “Strategic capital allocation is fundamental to the business and this financing strengthens our balance sheet at an attractive cost of capital for our business and shareholders,” said GTI Founder and CEO Ben Kovler. “We are well-positioned to capitalize on the attractive market opportunities in front of us. The proceeds will fuel our aggressive growth plans for faster route-to-market in key markets like New Jersey, as well as pursue expansion opportunities that broaden the reach of our brand portfolio.”

 


Debra BorchardtDebra BorchardtMay 14, 2019
brody-tilray-pack1-1280x675.jpg

3min2290

Tilray, Inc. (Nasdaq: TLRY) reported that its net loss for the quarter was $30.3 million or $0.32 per share compared to a loss of $5.2 million or $0.07 per share for the prior year period. Even though the revenue increased by 195.1% to $23.0 (C$31.0) million, versus last year’s $7.8 million – it was less than the net loss. The non-GAAP adjusted net loss for the quarter was $25.2 million or $0.27 per share for the first quarter of 2019.

The company attributed the increase in revenue to the legalization of Canadian adult-use in 2018 and the addition of hemp food sales from the Manitoba Harvest acquisition. Tilray attributed the rise in net losses to non-recurring acquisition-related charges. The company reported that the adjusted EBITDA grew to a loss of $14.6 million versus last year’s loss of $3.2 million for the same time period. period.

Tilray said that the increased “net loss and Adjusted EBITDA declines were primarily due to the increase in operating expenses related to growth initiatives, the addition of Manitoba Harvest, and the expansion of international teams.”

“We are pleased with our first quarter results and the ongoing, substantial progress our team has made to position Tilray as a global leader in the cannabis industry,” said Brendan Kennedy, Tilray President and CEO. “We have made significant progress integrating our recent acquisitions of Manitoba Harvest and Natura Naturals, accelerating our entry into the United States hemp and CBD markets, and increasing our production and manufacturing capacity in North America and Europe. As we expand our operations around the world, we remain focused on making disciplined investments to maximize the multiple paths to value creation we are aggressively pursuing for our visionary investors.”

Prices Fall

While the company sold more kilograms, the prices fell for what it sold. Total kilogram equivalents sold increased over two-fold to 3,012 kilograms from 1,299 kilograms in the prior year period. Unfortunately for the company, the average net selling price per gram decreased to $5.60 (C$7.54) compared to $5.94 (C$8.00) in the prior year period. The average net selling price excluding excise taxes was $5.28 (C$7.02) per gram for the first quarter of 2019.

The company continues to increase production. Tilray is making an investment of $32.6 million to increase its Canadian production and manufacturing footprint by 203,000 square feet across three facilities in Nanaimo, British Columbia, Leamington, Ontario, and London, Ontario. The investment will expand Tilray’s total production and manufacturing footprint from 1.1 million to 1.3 million square feet worldwide.


William SumnerWilliam SumnerMay 9, 2019
daily_hit004-1280x533.png

4min2850

It’s time for your Daily Hit of cannabis financial news for May 8, 2019.

On the Site

CalCannabis: Why Such a Debacle?

We were prompted to write this article by Joe Kukura’s article “Pot Growers Nipped in the Bud by Bureaucratic Bungle.” We agree with the article. CalCannabis created a gigantic debacle with its licensing of cultivators. However, a more accurate statement is, “CalCannabis is a gigantic blunder.”

Marketing Matters: More… On The Art Of Branding & Identity

Defining your brand is paramount. Define who you are, what you stand for and who you are not. Provide a relevant point of view to the market you serve and develop your brand message & voice to match it.

In Other News

Nug

Nug Inc. announced today that it has raised $15 million in a Series A Funding round. Nug initially set out to raise $10 million but the offering was oversubscribed and the company raised an additional $5 million. The company will use the proceeds from this fundraising round to expand its manufacturing, distribution and branding capacities. “This latest capital infusion represents an ongoing phase of aggressive growth for NUG and is indicative of an auspicious future, validating our team’s relentless ambition and commitment to developing top notch products, innovative services and technology,” said Dr. John Oram, CEO and Founder of NUG.

Abacus Health Products

Abacus Health Products, Inc. (CSE: ABCS) announced that it has raised $34.5 million through a bought deal offering of 2,464,450 units of the company, which includes the full exercise of the underwriters’ over-allotment option. A syndicate of underwriters, including Eight Capital, GMP Securities LP, Cormark Securities Inc., Haywood Securities Inc. and Paradigm Capital Inc. led the offering. The company intends on using the proceed from the offering for general working capital, increase international distribution of products, and to ramp up its marketing and sales programs to seek to increase retail pharmacy store locations from 1,100 to over 10,000.

Tilray

Tilray Inc. (NASDAQ: TLRY) said today that it plans to make an investment of $32.6 million to increase the company’s Canadian cannabis production manufacturing footprint from 1.1 million to 1.3 million square feet across three facilities located in Leamington, Ontario; London, Ontario; and Nanaimo, British Columbia. The investment is expected to create around 100 news jobs.


StaffStaffMarch 21, 2019
ClosingBell-tilray-Nasdaq-1280x854.jpg

8min3880

Guest Post by Nicolas Chahine, InvestorPlace Contributor

We often hear jokes about the lofty valuations of cannabis stocks. They have huge market capitalizations with only a tiny fraction of them in actual revenues. Tilray Inc. (NASDAQ: TLRY) is perhaps the poster child for that joke since its short squeeze that occurred last September. Then Tilray stock skyrocketed to $300 per share in a day, but only to perhaps mark the absolute top forever.

First, let me assure you that I am not a perma-bull on pot stocks. Yes, I only trade them from the long side, but I use the technicals to guide my decisions. A few weeks ago, I shared a long entry opportunity in Tilray stock and it paid quickly.

On Monday, TLRY reported earnings and investors are happy with what they saw because TLRY stock was spiking on the headline. But in classic TLRY fashion, the knee jerk reaction was violent as the stock fell $5, then rallied at $4. 

The results were mixed as management beat the sales expectations but also reported some extra expenses. For now, this is something Wall Street should ignore for as long as TLRY is a growth stock.

If this were a mature company, then investors can demand tighter profit controls, but this is a situation where the cannabis companies are plowing into completely new territory so they deserve a lot of leeway, more so than usual in fact.

The cannabis industry is still in its infancy on Wall Street. Even the so-called experts rely more on hunches and guessing to forecast the fundamentals. So perhaps until there is enough history to establish tangible expectations, I greatly rely on the technicals to guide me. Charts don’t lie and they outline the trends and important levels.

However, relying on charts doesn’t mean I completely dismiss the importance of the company metrics. Perhaps the most important one that TLRY reported last night was that it sold 2,053 kilos, which is three times that of last year. This combined with a 110% increase in revenues for the same period, which tells me that the company is executing well on its growth plans.

TLRY’s Chief Executive Officer Brendan Kennedy explained away the margin pressures by highlighting the expansion of its facilities. The company added seven new facilities, so the ramp-up time will keep profitability at odds until the revenues catch up to the expenses. Overspending is the necessary evil that growth companies have to endure.

Meanwhile, they maintain a relatively healthy balance sheet with $500 million in cash. This will ensure that they are able to pursue their next focus areas in the U.S. and Europe. This is not only by targeting the recreational legalization trends, but this also includes making the CBD and medical applications.

Bottom Line on Tilray Stock

In short, the company is succeeding in its mission, so Tilray stock should have more upside potential in the long run. Those who want to bet on its success for years to come need not to worry about the minutia of action here. Moreover, they are not going at it alone. Management struck a partnership with Anheuser-Busch InBev (NYSE: BUD), which validates TLRY’s efforts in my opinion. If it’s good enough for a massive company like BUD, then it’s good enough for the general investor.

Meanwhile, for those who prefer to trade the stock short term instead, the technicals can definitely provide a road map.

Year-to-date, TLRY stock came into the earnings event only up 2.4% compared to the S&P 500’s 12% for the same period. Clearly, the stock is stuck below $80 per share since December. Even worse is how TLRY compares to Canopy Growth (NYSE: CGC), Cronos (NASDAQ: CRON) and Aurora Cannabis (NYSE: ACB), which are up 70%, 108% and 100%, respectively, for the same period.

The overnight bounce in Tilray stock brought it into potential resistance. The area around $76 to $78 per share has been pivotal for months. This usually creates resistance as both bulls and bears want to win the battle there. In January, the TLRY bulls were able to overcome it, but only for a few days. Unlike the stock market in general, TLRY has failed to recover the ledges from which they crashed into the Christmas correction.

Specifically, $77.50 is my area of interest. If they close TLRY above it and successfully retest it for footing, I’d consider it an opportunity to trade the upside potential to recover the January highs. But even then, there are areas of resistance here and at $82 per share. So I would need to see a clear breach of the first line of resistance before I chase it long.

As for support, the bears could get more of an upper hand if they can break through $70 per share. Oddly enough, Tilray stock retested its December lows just a few days ago. This is happening while the S&P 500 is still on a tear. The wound is still fresh. Below it, there is a trap door to the mid-fifties. This is not a forecast, but merely one of the available scenarios at hand.

It is best to wait for the break out from the zones noted before chasing either the upside or the downside potentials.

As of this writing Nicolas Chahine did not hold a position in any of the aforementioned securities.

 


Debra BorchardtDebra BorchardtMarch 18, 2019
ClosingBell-tilray-Nasdaq-1280x854.jpg

4min4520

Tilray Inc. (TLRY) delivered its full year and fourth quarter results on Monday after the closing bell. The stock initially dipped, but then reversed course to move higher by 3% to lately trade at $74.50.

Fourth Quarter

Revenue increased to $15.5(C$20.9) million, up 203.8% compared to the fourth quarter of last year and beating the Yahoo! Finance analyst average estimate for $14.15 million. The company said that revenue was driven by bulk sales, inaugural sales in the Canadian adult-use market and accelerated wholesale distribution in export markets.

Estimates were all over the map with lows at $12 million and highs at $18 million. The company was facing criticism over inventory issues for the fourth quarter as demand for adult use cannabis surprised most cannabis companies in Canada. Tellingly, the company sent out a tweet right before the earnings were released saying that its inventory levels were all stocked up.

“2018 was a very successful year for Tilray with many corporate milestones. Our team made significant progress on our long-term initiatives including increasing production capacity, expanding and strengthening strategic partnerships, and acquiring complementary businesses to accelerate our future growth and leadership position in medical and adult-use cannabis,” commented Brendan Kennedy, President and Chief Executive Officer of Tilray.

Net loss for the quarter was $31.0 million or $0.33 per share compared to $3.0 million or $0.04 per share for the prior year period. Net loss includes non-cash stock-based compensation charges of $4.1 million compared to $34 thousand in the prior year period. Adjusted EBITDA was a loss of $17.8 million compared to a loss of $2.1 million the prior year period. The increased net loss and Adjusted EBITDA declines were primarily due to the increase in operating expenses related to growth initiatives, expansion of international teams and costs related to financings and M&A activities.

Total kilogram equivalents sold increased almost three-fold to 2,053 kilograms from 694 kilograms in the prior year period.  The average net selling price per gram increased to $7.52(C$10.05) compared to $7.13(C$9.12) in the prior year period.

Full Year Results

The company’s revenue for 2018 increased to $43.1(C$56.4) million, up 110.0% compared to last year. The increase in revenue was driven by bulk sales, the inaugural sales for the Canadian adult-use market (which began on Oct. 17) and accelerated wholesale distribution in export markets.

The net loss for the year was $67.7 million, or $0.82 per share, compared to $7.8 million, or $0.10 per share, for 2017. Net loss includes non-cash stock-based compensation charges of $21.0 million compared to a $0.1 million charge in the prior year.

Adjusted EBITDA was a loss of $33.1 million compared to a loss of $5.5 million the prior year. The increased net loss and Adjusted EBITDA declines were primarily due to the increase in operating expenses related to continued growth, expansion of international teams, and costs related to financings and the initial public offering (“IPO”).

Total kilogram equivalents sold increased over two-fold to 6,478 kilograms from 3,024 kilograms in the prior year. Average net selling price per gram increased to $6.61(C$8.59) compared to $6.52(C$8.42) in the prior year. In 2018, there was significant revenue growth for extract products compared to dried flower, where extracts represented 49% of the sales mix in 2018 compared to 20% in 2017.

 



About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 2 days

Executive Spotlight: Liesl Bernard, CEO of

@GreenMarketRpt – 2 days

RT : Our Founder & CEO was featured in the Executive Spotlight! Check out the full article here;

@GreenMarketRpt – 2 days

Our biggest fans this week: WallandBroad, cosmo_crator. Thank you! via

Back to Top

You have Successfully Subscribed!